Fig. 1: AXL plays a pivotal role in the survival of HER2-aberrant tumor cancers. | npj Precision Oncology

Fig. 1: AXL plays a pivotal role in the survival of HER2-aberrant tumor cancers.

From: AXL–SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers

Fig. 1: AXL plays a pivotal role in the survival of HER2-aberrant tumor cancers.The alternative text for this image may have been generated using AI.

A Calu-3 and MKN7 cell viability after 9 days of treatment with the indicated concentrations of mobocertinib, replenished every 72 h. MTT assays evaluating the effect of a combination of mobocertinib (0.1 or 0.01 μmol/L) and knockdown of 56 receptor tyrosine kinases on B Calu-3 and C MKN7 cell viability in comparison to cells treated with nonspecific control siRNA and incubated with mobocertinib. MTT assays were conducted to evaluate the impact of a combination of mobocertinib for 72 h and the knockdown of 56 receptor tyrosine kinases sourced from the Silencer® Select human kinase siRNA library. The effects of the top 10 genes indicated by a red line in the panel are shown. D Western blotting of Calu-3 and MKN7 cells treated with mobocertinib (0.01 or 0.1 μmol/L) for the indicated durations. E MTT assays assessing cell viability were assessed in Calu-3 and MKN7 treated with nonspecific control siRNA or AXL-specific siRNAs, and incubated with or without mobocertinib *P < 0.05 (one-way ANOVA). Western blotting of F Calu-3 and G MKN7 cells treated with nonspecific control siRNA or AXL-specific siRNA, and incubated with or without mobocertinib for 4 h.

Back to article page